article thumbnail

Unlearn Raises $50M to Accelerate AI-Powered Clinical Trials with Digital Twins

HIT Consultant

AI-Powered Clinical Trials with Digital Twins Founded in 2017, Unlearn has consistently pushed the boundaries of AI in clinical research. Regulatory Backing for Innovation Unlearn understands the importance of regulatory compliance. founder and CEO of Unlearn.

article thumbnail

Five Reasons why the FDA got it Right with Digital Health

The Digital Health Corner

The FDA recently announced its Digital Health Innovation Action Plan. Digital health differs significantly from drugs and traditional medical devices around which the FDA has developed its structure and policies over decades. The FDA will have new digital health experts. This plan was both important and necessary.

FDA 87
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Guidance Shows a Regulatory Path Forward for Interoperable Devices

Exeed Regulatory Compliance

A new FDA guidance offers helpful recommendations for design and premarket submission. According to a 2018 Deloitte Consulting report, the market for interconnected medical devices is expected to grow from $15 billion in 2017 to $52 billion by 2025. Medical device industry is changing fast!

FDA 52
article thumbnail

Unpacking Averages: Using NLP to Assess FDA’s Compliance with Notice and Comment in Guidance Development

Health Law Advisor

Introduction Let’s say FDA proposed a guidance document that would change the definition of “low cholesterol” for health claims. Now let’s say that when FDA finalized the guidance, instead of addressing that topic, FDA banned Beluga caviar.

FDA 52
article thumbnail

FDA Unlocks the Key to Innovation in Interoperable Medical Devices

Exeed Regulatory Compliance

According to a 2018 report from Deloitte , the IoMT market is expected to grow from $41 billion in 2017 to $158 billion by 2022. Regulatory Breakthrough In a small step towards achieving the vision of interoperable medical devices, the FDA has recently authorized marketing of a novel software medical device using the De Novo Classification.

FDA 52
article thumbnail

AI Outperforms Ophthalmologists at Detecting Eye Disease

HIT Consultant

– The multi-center study evaluated the FDA-cleared EyeArt AI system against dilated eye exams performed by general ophthalmologists and retina specialists on the same cohort of 521 study participants. The study design was a prospective, pivotal, multi-center trial conducted from April 2017 to May 2018. Participants were ?18

FDA 98
article thumbnail

The Essentials of Software as a Medical Device (SaMD)

Dot Compliance

SaMD Regulatory and Compliance Challenges. SaMD presents challenges in the regulatory and compliance arena, given the rapid rate of innovation and its effects on the already expansive selection of existing and potential future SaMD solutions. QMS as Critical for SaMD Compliance.

FDA 52